Generic Velsipity Availability
Last updated on Jan 8, 2025.
Velsipity is a brand name of etrasimod, approved by the FDA in the following formulation(s):
VELSIPITY (etrasimod arginine - tablet;oral)
Has a generic version of Velsipity been approved?
No. There is currently no therapeutically equivalent version of Velsipity available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Velsipity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
Patent 10,301,262
Issued: May 28, 2019
Inventor(s): Blackburn Anthony C. & Castro Ryan O. & Hadd Mark Allen & Ma You-An & Montalban Antonio Garrido & Rueter Jaimie Karyn & Selvey Lee Alani & Shakya Sagar Raj & Carlos Marlon
Assignee(s): Arena Pharmaceuticals, Inc.The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1Preceptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).
Patent expiration dates:
- June 21, 2036✓✓
- June 21, 2036
-
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders
Patent 10,676,435
Issued: June 9, 2020
Inventor(s): Blackburn Anthony C. & Castro Ryan O. & Hadd Mark Allen & Ma You-An & Montalban Antonio Garrido & Rueter Jaimie Karyn & Selvey Lee Alani & Shakya Sagar Raj & Carlos Marlon
Assignee(s): Arena Pharmaceuticals, Inc.The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1Preceptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).
Patent expiration dates:
- June 21, 2036✓
- June 21, 2036
-
Methods of treating conditions related to the S1Preceptor
Patent 11,007,175
Issued: May 18, 2021
Inventor(s): Glicklich Alan & Kam Maria Matilde Sanchez & Shanahan William R.
Assignee(s): Arena Pharmaceuticals, Inc.Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
Patent expiration dates:
- January 6, 2036✓
- January 6, 2036
-
Patent 11,091,435
Patent expiration dates:
- June 21, 2036✓✓
- June 21, 2036
-
Patent 11,884,626
Patent expiration dates:
- June 21, 2036✓
- June 21, 2036
-
Patent 12,156,866
Patent expiration dates:
- January 6, 2036✓
- January 6, 2036
-
Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Patent 8,580,841
Issued: November 12, 2013
Inventor(s): Jones Robert M & Buzard Daniel J & Han Sangdon & Kim Sun Hee & Lehmann Juerg & Ullman Brett & Moody Jeanne V & Zhu Xiuwen & Stirn Scott
Assignee(s): Arena Pharmaceuticals, Inc.The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia):
Patent expiration dates:
- March 5, 2030✓✓
- March 5, 2030
-
Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Patent 9,126,932
Issued: September 8, 2015
Inventor(s): Jones Robert M. & Buzard Daniel J. & Han Sangdon & Kim Sun Hee & Lehmann Juerg & Ullman Brett & Moody Jeanne V. & Zhu Xiuwen & Stim Scott
Assignee(s): Arena Pharmaceuticals, Inc.The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
Patent expiration dates:
- July 22, 2029✓
- July 22, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 12, 2028 - NEW CHEMICAL ENTITY
More about Velsipity (etrasimod)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
